MAST3

Across TCGA pan-cancer cohorts, MAST3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAST3 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MAST3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MAST3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where MAST3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	II,III,IV	0.859	0.611	.005	36	view →
LUAD	OS	Tertile	All	1.000	0.694	.009	4	view →
PDAC	OS	Median	IV	0.836	0.491	.024	3	view →
HNSC	DFS	Tertile	III,IV	1.000	0.411	.040	2	view →
LSCC	DFS	Quartile	All	0.815	0.356	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAST3–CCRCC (OS)

Open the CCRCC breakdown →